Show MeThe 340B Drug Pricing Program is a federal mandate requiring drug manufacturers to sell outpatient drugs to eligible safety-net providers at a discount of at least 23.1 percent below the average manufacturer price. Congress created it in 1992 so that hospitals serving low-income patients could stretch scarce federal resources. Covered entities—certain hospitals, clinics, and health centers—buy discounted drugs, then bill insurers at standard rates and keep the difference. This "spread" fuels a USD 50 billion-plus annual market and a running policy war over whether the savings reach patients. Here is the mechanism, the numbers, and what the evidence actually shows.
The core mechanism: a discount without a spending cap
The 340B program is not a government grant. No federal money changes hands. Instead, the Health Resources and Services Administration (HRSA) requires manufacturers participating in Medicaid and Medicare Part B to extend a statutory discount to enrolled safety-net providers.
The discount is calculated against the average manufacturer price, or AMP. The minimum is 23.1 percent off AMP for most drugs, and deeper for brand drugs whose prices rise faster than inflation. Manufacturers must also offer this price as a condition of their Medicaid drug rebate agreement, so participation is effectively mandatory.
The financial engine is the "duplicate discount" prohibition, paired with the "spread." A covered entity buys a drug at the 340B price, then bills the patient's commercial insurer or Medicare at the negotiated rate. The gap between the discounted acquisition cost and the reimbursement is retained by the entity. Nothing in the statute requires the savings to be passed to the patient at the pharmacy counter.
In plain terms: the program subsidizes the institution, not the individual. That distinction sits at the center of nearly every controversy described below.
The patient mix that qualifies an entity
To enroll, a provider must meet a patient-mix threshold. Disproportionate share hospitals, or DSH hospitals, must have a Medicare DSH adjustment percentage above 11.75 percent. That single number is the most consequential eligibility gate in the program.
| Entity type | Qualifying threshold | Typical scale |
|---|---|---|
| DSH hospital | Medicare DSH adjustment above 11.75% | Larger urban hospitals |
| Children's hospital | Exempt from DSH threshold | Pediatric centers |
| Critical access hospital | No DSH threshold; rural designation | Small rural facilities |
| Sole community hospital | No DSH threshold | Isolated rural facilities |
| Federally qualified health center | Grant-funded safety-net clinic | Community clinics |
| Ryan White clinic | HIV/AIDS service designation | Specialty clinics |
Roughly 2,600 hospitals and tens of thousands of clinic sites are enrolled. The 11.75 percent threshold is a fixed statutory line, unchanged since the program's early years; a hospital at 11.74 percent is out, and one at 11.76 percent is in. This cliff-edge design is one reason hospital systems reorganize and acquire clinics—each newly affiliated site can be added as an eligible "child site."
340B versus the alternatives: a quantified comparison
Three discount mechanisms operate in U.S. drug purchasing, and they are not interchangeable. The comparison below shows how 340B differs from the Medicaid rebate and from ordinary commercial group purchasing.
| Dimension | 340B | Medicaid drug rebate | Commercial GPO contract |
|---|---|---|---|
| Discount floor | 23.1% off AMP | 23.1% off AMP plus inflation penalty | Negotiated, often 10-25% |
| Who captures savings | Covered entity (institution) | State Medicaid agency | Purchaser |
| Patient cost-sharing effect | Usually unchanged | Usually reduced | Negotiated |
| Federal spending | Zero direct outlay | Federal match on rebates | None |
| Audit oversight | HRSA periodic audits | CMS and state | Contractual |
The 340B discount floor and the Medicaid rebate floor are both 23.1 percent off AMP—a deliberate alignment written into law so manufacturers face a consistent baseline. The difference is where the money lands. In Medicaid, the rebate flows back to the state and federal government. In 340B, the spread stays with the provider.
A timeline of the program's expansion and conflict
The program has grown from a modest safety-net tool into one of the largest drug-purchasing channels in the country. The arc below traces the key turns.
| Year | Event | Effect |
|---|---|---|
| 1992 | Section 340B enacted | Program created for safety-net providers |
| 1996 | HRSA issues final guidance | Enrollment and audit framework set |
| 2010 | Affordable Care Act expansion | Eligibility broadened; covered entities multiply |
| 2015 | Hospital eligibility scrutiny begins | Dispute over off-site clinics intensifies |
| 2018 | Medicare OPPS payment cut to ASP minus 22.5% | Hospitals challenge in court |
| 2022 | Supreme Court rules against the cut | Payment reduction struck down |
| 2023 | Manufacturer restrictions on contract pharmacies spread | HRSA enforcement fights escalate |
| 2025 | Continued legislative proposals to cap or reform | Program remains contested |
The 2018 payment cut was the sharpest flashpoint. Medicare reduced reimbursement for 340B-acquired drugs in outpatient departments to average sales price minus 22.5 percent, arguing the program had outgrown its purpose. The Supreme Court's 2022 decision in American Hospital Association v. Becerra held that the agency lacked authority for the cut, forcing retroactive repayment.
The contract pharmacy dispute and the counterintuitive edge case
Here is the non-obvious part. The 340B statute says nothing about contract pharmacies—retail outlets that dispense on behalf of covered entities. HRSA allowed them informally, and their use exploded, letting a single hospital route prescriptions through dozens of retail locations.
Manufacturers pushed back starting around 2020, imposing conditions and refusing discounts on drugs dispensed at contract pharmacies. By 2024, more than 20 manufacturers had some form of restriction. The result is a patchwork where an identical drug costs differently depending on which pharmacy dispenses it.
The counterintuitive mechanism: the more pharmacies a covered entity adds, the more of its community—including insured, higher-income patients—flows through the discounted channel. The program's original target was the uninsured and underinsured. Contract pharmacy growth widened the capture to commercially insured patients who would have been served anyway. This is the strongest evidence-based critique, and it is a structural drift, not a fraud claim.
A 2021 Health Affairs analysis found that 340B hospitals, on average, provided a similar or modestly higher share of uncompensated care than non-340B peers, but the gap was far smaller than the discount margin implied. In plain terms: the discount is larger than the charity care the discount is meant to fund.
Where the money actually goes
The spread is real and large. Total 340B drug purchases were estimated at roughly USD 50 billion to USD 60 billion in recent years, with the discount value—the gap between 340B price and market price—running in the range of USD 8 billion to USD 12 billion annually, depending on the estimate.
Hospitals report using these dollars for oncology services, infusion centers, and uncompensated care. Oncology is the biggest single driver: cancer drugs are expensive, administered in outpatient settings, and often billed to Medicare Part B at rates well above the 340B acquisition cost. A single patient's course of therapy can generate tens of thousands of dollars of spread.
The safety-critical caveat: patient out-of-pocket costs are generally based on the billed charge, not the 340B acquisition price. A patient with coinsurance can therefore pay a percentage of a price far above what the hospital paid. That is legal, but it is the mechanism critics cite when they argue the program's savings do not reach the bedside.
What providers and policymakers can actually do
For clinicians and administrators inside the system, the practical levers are concrete.
- Verify every off-site clinic's eligibility before billing 340B, since an ineligible site triggers repayment.
- Reconcile 340B purchases against claims to prevent duplicate discounts, the most common audit finding.
- Document how savings fund uncompensated care, which strengthens both compliance and public defense.
- Track manufacturer contract-pharmacy restrictions, since they change dispensing economics site by site.
- Screen patient cost-sharing so that coinsurance is calculated fairly rather than on an inflated charge.
Red flags that warrant immediate internal review:
- A child site added after a hospital acquisition without a fresh eligibility determination.
- Contract pharmacy volume that far exceeds the covered entity's own patient population.
- Claims billed to Medicaid without excluding 340B-purchased drugs.
- Oncology infusion revenue that dominates the entity's 340B spread.
The limits of the evidence
No randomized trial exists here, and none can. The program is a policy, not a therapy, so the literature relies on observational comparisons of 340B and non-340B hospitals. These studies cannot fully separate the program's effect from the fact that qualifying hospitals are, by definition, different from non-qualifying ones.
The honest summary: the mechanism is well documented, the discount floor is fixed at 23.1 percent, and the eligibility threshold sits at 11.75 percent for DSH hospitals—three numbers that anchor the whole system. Whether the resulting USD 8 billion to USD 12 billion in annual savings delivers more charity care than it costs in higher drug spending is genuinely contested. Policymakers are weighing reforms in 2025 and 2026, and any change to the eligibility threshold or the discount floor would reshape the economics overnight. The mechanism is clear; the verdict on whether it works as intended is not.